Nuplazid 34 MG capsule 30S
Ended Awarded Last action
- Contract number
- SPE2DR26FQLP6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,924
Award facts
- Contract value 100% obligated
- $3,923.82 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $3,923.82 to DMS Pharmaceutical Group Inc. for Nuplazid (pimavanserin) 34 mg capsules (30-count) on January 26, 2026, with completion targeted for February 17, 2026. This firm fixed-price delivery order was awarded without a set-aside designation, reflecting DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement. The pharmaceutical products will be delivered to Park Ridge, Illinois, where DMS Pharmaceutical Group maintains its headquarters as a woman-owned small business pharmaceutical wholesaler.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) established through the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to support recurring medical supply needs across Department of Defense healthcare facilities worldwide. The underlying IDC, designated SPE2DR, was awarded on November 13, 2025, with a $499,999,999 ceiling value and extends through December 31, 2036. DMS Pharmaceutical Group serves as a critical regional pharmaceutical supplier under this program, authorized to deliver comprehensive pharmaceutical products including branded and generic prescription drugs, biologics, and medical consumables to support military healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FQLP6?
SPE2DR26FQLP6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 26, 2026.
How much is contract SPE2DR26FQLP6 worth?
The government has obligated $3,924 on SPE2DR26FQLP6.
Is contract SPE2DR26FQLP6 an order under another contract?
Yes. SPE2DR26FQLP6 is a delivery order under SPE2DR25D9354, an indefinite delivery contract.
Was contract SPE2DR26FQLP6 competed?
The extent of competition for SPE2DR26FQLP6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award